Reply to: ‘evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies’

"Reply to: ‘evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies’." Expert Review of Respiratory Medicine, 15(4), pp. 577–578

Acknowledgments

Editorial support (in the form of writing assistance, collating author comments, grammatical editing and referencing) was provided by Chrystelle Rasamison, at Fishawack Indicia Ltd, part of Fishawack Health, and was funded by GSK. Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC).

Declaration of interest

MK Han has received personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Merck and Mylan, and research support from Novartis and Sunovion. DA Lipson is an employee of GSK and holds stocks/shares in GSK. D Singh has received personal fees from GSK, Cipla, Genentech and Peptinnovate, and personal fees and grant support from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Theravance and Verona. FJ Martinez has received personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Inova Fairfax Health System, Methodist Hospital, National Society for Continuing Education/Haymarket, Novartis, Pearl Pharmaceuticals, PeerView Communications, Physicians Education Resource, Chiesi, CSL Behring, Sunovion, University of Alabama Birmingham, Physicians Education Resource, Canadian Respiratory Network, CME Outfitters, Teva, Vindico and Dartmouth, non-financial support from Bioscale/ProterrixBio, Nitto and Zambon, personal fees from MD Magazine, New York University, UpToDate, WebMD/MedScape, Patara/Respivant, Rockpointe, Rare Disease Healthcare Communications, France Foundation and Prime Education, and other support from AstraZeneca, Boehringer Ingelheim, Bioscale/ProterrixBio, Afferent/Merck, Gilead, Patara/Respivant, Stromedix/Biogen, Veracyte, Prometic, Bayer, Bridge Biotherapeutics, Bristol Myers Squibb, Physicians Education Resource, ProMedior/Roche, twoXR, and Gala. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

The IMPACT trial was funded by GSK (study CTT116855; NCT02164513). The funders of the study had a role in the study design, data analysis, data interpretation and writing of the report.